NEW YORK (GenomeWeb) – Seattle-based NanoString Technologies announced today that health insurer Cigna has issued a positive coverage decision for the Prosigna Breast Cancer Gene Signature Assay.
The decision provides Cigna's approximately 13 million members with access to the test.
"This positive coverage decision is in line with updated ASCO guidelines released in February, wherein Prosigna is considered medically necessary to assess the necessity of adjuvant chemotherapy in ER-positive, HER2-negative, node-negative breast cancer patients, when adjuvant chemotherapy is not precluded due to any other factor," NanoString said in a statement. CEO Brad Gray estimated that 80 percent of patients in the US indicated for Prosigna are now covere
Read Full Article »